NASDAQ:CLSN Celsion Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celsion Co. Please log in to your account or sign up in order to add this asset to your watchlist. $1.88 +0.03 (+1.62%) (As of 06/29/2022 04:00 PM ET) Add Compare Share Today's Range$1.84▼$1.8950-Day Range$1.81▼$3.2852-Week Range$1.80▼$19.80Volume19,252 shsAverage Volume192,232 shsMarket Capitalization$13.35 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celsion and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSN Stock Forecast (MarketRank)Overall MarketRank™2.19 out of 5 starsMedical Sector394th out of 1,432 stocksPharmaceutical Preparations Industry167th out of 685 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingCelsion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Celsion has a forecasted upside of 751.1% from its current price of $1.88.Amount of Analyst CoverageCelsion has only been the subject of 1 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesCelsion has received 387 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCelsion has received 177 “underperform” votes. (Add your “underperform” vote.)Community SentimentCelsion has received 68.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote “Outperform” if you believe CLSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCelsion does not currently pay a dividend.Dividend GrowthCelsion does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celsion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,370.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.58% of the stock of Celsion is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Celsion are expected to grow in the coming year, from ($4.38) to ($4.07) per share.Price to Book Value per Share RatioCelsion has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celsion (NASDAQ:CLSN)Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Read More CLSN Stock News HeadlinesJune 23, 2022 | americanbankingnews.comCelsion (NASDAQ:CLSN) Receives New Coverage from Analysts at StockNews.comJune 21, 2022 | globenewswire.comCelsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - GlobeNewswireJune 18, 2022 | benzinga.comCLSN: OVATION 2 Study 85% Enrolled… - Benzinga - BenzingaJune 13, 2022 | finance.yahoo.comCLSN: OVATION 2 Study 85% Enrolled…June 9, 2022 | businesswire.comGlobal Nucleic Acid Based Gene Therapy Market to 2031 - Featuring BioMedica, Transgene and Copernicus Therapeutics Among Others - ResearchAndMarkets.com - Business WireJune 9, 2022 | americanbankingnews.comCelsion Co. (NASDAQ:CLSN) Expected to Announce Quarterly Sales of $110,000.00June 6, 2022 | americanbankingnews.comStockNews.com Begins Coverage on Celsion (NASDAQ:CLSN)May 30, 2022 | finance.yahoo.comNucleic Acid Based Gene Therapy Global Market Report 2022 - Yahoo FinanceMay 20, 2022 | streetinsider.comAdvanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression - StreetInsider.comMay 17, 2022 | globenewswire.comCelsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update - GlobeNewswireMay 16, 2022 | benzinga.comCelsion: Q1 Earnings Insights - Benzinga - BenzingaMay 14, 2022 | benzinga.comEarnings Outlook For CelsionMay 14, 2022 | seekingalpha.comCelsion Q4 2022 Earnings PreviewSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSN CUSIPN/A CIK749647 Webwww.celsion.com Phone(609) 896-9100Fax609-896-2200Employees27Year Founded1982Company Calendar Last Earnings5/16/2022Today6/29/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+751.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20.77 million Net Margins-5,110.80% Pretax Margin-5,387.60% Return on Equity-45.34% Return on Assets-33.97% Debt Debt-to-Equity Ratio0.13 Current Ratio6.60 Quick Ratio6.60 Sales & Book Value Annual Sales$500 thousand Price / Sales26.69 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / Book0.19Miscellaneous Outstanding Shares7,099,000Free Float6,774,000Market Cap$13.35 million OptionableOptionable Beta2.29 Social Links Celsion Frequently Asked Questions Should I buy or sell Celsion stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celsion stock. View analyst ratings for Celsion or view top-rated stocks. What is Celsion's stock price forecast for 2022? 2 analysts have issued twelve-month price targets for Celsion's shares. Their CLSN stock forecasts range from $16.00 to $16.00. On average, they expect Celsion's share price to reach $16.00 in the next year. This suggests a possible upside of 751.1% from the stock's current price. View analysts' price targets for Celsion or view top-rated stocks among Wall Street analysts. How has Celsion's stock performed in 2022? Celsion's stock was trading at $8.10 at the start of the year. Since then, CLSN stock has decreased by 76.8% and is now trading at $1.88. View the best growth stocks for 2022 here. When is Celsion's next earnings date? Celsion is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Celsion. How were Celsion's earnings last quarter? Celsion Co. (NASDAQ:CLSN) posted its earnings results on Monday, May, 16th. The biotechnology company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.83. Celsion had a negative net margin of 5,110.80% and a negative trailing twelve-month return on equity of 45.34%. During the same period last year, the firm earned ($1.35) earnings per share. View Celsion's earnings history. When did Celsion's stock split? How did Celsion's stock split work? Celsion's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split. Who are Celsion's key executives? Celsion's management team includes the following people: Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 71, Pay $1.01M)Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 65, Pay $528.54k)Dr. Khursheed Anwer M.B.A., Ph.D., Exec. VP & Chief Scientific Officer (Age 62, Pay $511.92k)Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 63, Pay $586.54k)Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 64)Ms. Marianne M. Lambertson, VP of Communications & Investor Relations Who are some of Celsion's key competitors? Some companies that are related to Celsion include Angion Biomedica (ANGN), Zynerba Pharmaceuticals (ZYNE), Elite Pharmaceuticals (ELTP), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Athenex (ATNX), Galecto (GLTO), SELLAS Life Sciences Group (SLS), Aptorum Group (APM), Processa Pharmaceuticals (PCSA), Vaccinex (VCNX), Chemomab Therapeutics (CMMB), RedHill Biopharma (RDHL), Novan (NOVN) and Hepion Pharmaceuticals (HEPA). View all of CLSN's competitors. What other stocks do shareholders of Celsion own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL). What is Celsion's stock symbol? Celsion trades on the NASDAQ under the ticker symbol "CLSN." How do I buy shares of Celsion? Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celsion's stock price today? One share of CLSN stock can currently be purchased for approximately $1.88. How much money does Celsion make? Celsion (NASDAQ:CLSN) has a market capitalization of $13.35 million and generates $500 thousand in revenue each year. How many employees does Celsion have? Celsion employs 27 workers across the globe. When was Celsion founded? Celsion was founded in 1982. How can I contact Celsion? Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The official website for Celsion is www.celsion.com. The biotechnology company can be reached via phone at (609) 896-9100, via email at [email protected], or via fax at 609-896-2200. This page (NASDAQ:CLSN) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here